Research analysts at Northland Securities started coverage on shares of Viveve Medical (NASDAQ:VIVE) in a research note issued to investors on Friday, MarketBeat reports. The brokerage set an “outperform” rating and a $8.00 price target on the stock. Northland Securities’ price target would indicate a potential upside of 61.29% from the company’s previous close.
VIVE has been the topic of a number of other research reports. Mizuho started coverage on shares of Viveve Medical in a research report on Thursday, November 16th. They set a “buy” rating and a $10.00 price target on the stock. Cowen set a $11.00 price objective on shares of Viveve Medical and gave the stock a “buy” rating in a research report on Monday, October 23rd. Finally, ValuEngine cut shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $10.00.
Shares of Viveve Medical (NASDAQ VIVE) opened at $4.96 on Friday. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72. Viveve Medical has a 1 year low of $3.75 and a 1 year high of $11.16.
Viveve Medical (NASDAQ:VIVE) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.08). The firm had revenue of $4.07 million for the quarter, compared to the consensus estimate of $4.10 million. Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The business’s revenue was up 120.1% compared to the same quarter last year. During the same period last year, the company posted ($0.46) EPS. equities research analysts forecast that Viveve Medical will post -2.04 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in the company. Neuberger Berman Group LLC bought a new position in shares of Viveve Medical during the 3rd quarter worth about $419,000. Granahan Investment Management Inc. MA boosted its position in shares of Viveve Medical by 32.6% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 102,147 shares of the company’s stock worth $535,000 after purchasing an additional 25,097 shares in the last quarter. RTW Investments LP boosted its position in shares of Viveve Medical by 18.8% during the 3rd quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock worth $7,719,000 after purchasing an additional 233,585 shares in the last quarter. ING Groep NV boosted its position in shares of Viveve Medical by 93.7% during the 3rd quarter. ING Groep NV now owns 325,000 shares of the company’s stock worth $1,703,000 after purchasing an additional 157,200 shares in the last quarter. Finally, California State Teachers Retirement System bought a new position in shares of Viveve Medical during the 2nd quarter worth about $190,000. 66.90% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Viveve Medical (VIVE) Research Coverage Started at Northland Securities” was originally published by Equities Focus and is the sole property of of Equities Focus. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.equitiesfocus.com/2018/01/07/viveve-medical-vive-research-coverage-started-at-northland-securities.html.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.